June 1, 2023

Proteomedix appoints Ralph Schiess as CEO

Zurich-Schlieren, Switzerland, June 1, 2023. Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, today announced that its board of directors has appointed Ralph Schiess as Chief Executive Officer.

Ralph Schiess is succeeding Helge Lubenow. He co-founded Proteomedix with Christian Brühlmann, CBO with the vision to position Proteomedix as an important player in the early detection of prostate cancer.

“The board of directors would like to thank Helge Lubenow for her commitment and support of the business during her time as CEO. Helge shaped the company`s transformation to a commercial stage organization and took important steps towards the successful market development of Proclarix," commented Harry Welten, Chairman of the Board of Directors of Proteomedix.

“Proclarix, a CE-IVDR marked product available in several countries across Europe, is seeing adoption in patient management as it is recommended by both the European Association of Urology (EAU) and the American Urology Association (AUA) guidelines for the early detection of prostate cancer" said Helge Lubenow and added: "The strong clinical evidence was also important for our recent licensing deal."

"I’m excited to lead the company in this next phase as we expand the use of Proclarix," said Ralph Schiess and added: “We want to further leverage the potential of our biomarker platform becoming a multiomics leader in the oncology sector. Additionally, we intend to build on top of our existing collaboration to commercializing Proclarix in the U.S. and expand our commercial partnering activities to other markets/territories. With the extension of the Board of Directors with Werner Böing, former Chief Information Officer at Roche Diagnostics, we are well prepared for the digital change of future diagnostics."

About Proteomedix

Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnosis. The company has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product Proclarix® is a blood based prostate cancer test panel and risk score currently available in Europe. Proteomedix is located in the Bio-Technopark of Zurich-Schlieren, Switzerland. For more information, visit www.proteomedix.com.

For further details, please contact:
Dr. Ralph Schiess, CEO    

Christian Brühlmann, CBO